Cross-source evidence timeline
Ganirelix research timeline
Follow 42 selected, directly cited source records from July 29, 1999 through July 2, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT06745466↗
PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT05954962↗
PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.↗
PubMed lists PMID 36279721 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 21, 2022 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT03142893↗
PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT04037605↗
PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA219454↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 219454 with status AP dated 2025-06-27, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT05751252↗
PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA218855↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 218855 with status AP dated 2025-04-23, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2024
Clinical trials
ClinicalTrials.gov record NCT06091436↗
PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00703014↗
PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00702273↗
PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00988260↗
PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00696800↗
PeptideScanner retained ClinicalTrials.gov record NCT00696800 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-06-20, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01304511↗
PeptideScanner retained ClinicalTrials.gov record NCT01304511 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-04-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix.↗
PubMed lists PMID 28721542 in In silico pharmacology as Journal Article, with publication-date metadata of 2017-07-18 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 18, 2017 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2023
Regulatory
Drugs@FDA application ANDA216075↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 216075 with status AP dated 2023-11-16, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA215658↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 215658 with status AP dated 2023-02-28, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2022
Regulatory
Drugs@FDA application ANDA214996↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 214996 with status AP dated 2022-06-06, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA212613↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 212613 with status AP dated 2022-04-07, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00724789↗
PeptideScanner retained ClinicalTrials.gov record NCT00724789 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-02-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT03300518↗
PeptideScanner retained ClinicalTrials.gov record NCT03300518 at 2026-11-15T22:03:26.540Z. Its registry update date was 2022-01-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT00608062↗
PeptideScanner retained ClinicalTrials.gov record NCT00608062 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00589134↗
PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2019
Literature metadata
Radioimmunoassay of ganirelix in plasma or serum.↗
PubMed lists PMID 8354719 in Journal of immunoassay as Comparative Study, Journal Article, with publication-date metadata of 1993-09 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 1993 · month precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT03051087↗
PeptideScanner retained ClinicalTrials.gov record NCT03051087 at 2026-11-15T22:03:26.540Z. Its registry update date was 2019-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Ganirelix acetate.↗
PubMed lists PMID 10582819 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 1999-11-15 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 15, 1999 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2018
Clinical trials
ClinicalTrials.gov record NCT01153581↗
PeptideScanner retained ClinicalTrials.gov record NCT01153581 at 2026-11-15T22:03:26.540Z. Its registry update date was 2018-12-13, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA204246↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 204246 with status AP dated 2018-11-30, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Literature metadata
Ganirelix.↗
PubMed lists PMID 10718102 in Drugs as Journal Article, Review, with publication-date metadata of 2000-01 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 2000 · month precisionAdded to PeptideScanner November 15, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT00734279↗
PeptideScanner retained ClinicalTrials.gov record NCT00734279 at 2026-11-15T22:03:26.540Z. Its registry update date was 2017-12-26, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2016
Literature metadata
Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'.↗
PubMed lists PMID 20504085 in Acta obstetricia et gynecologica Scandinavica as Journal Article, Multicenter Study, with publication-date metadata of 2010-06 (month precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 2010 · month precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00757185↗
PeptideScanner retained ClinicalTrials.gov record NCT00757185 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-07-04, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01816321↗
PeptideScanner retained ClinicalTrials.gov record NCT01816321 at 2026-11-15T22:03:26.540Z. Its registry update date was 2016-06-23, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2015
Clinical trials
ClinicalTrials.gov record NCT00225433↗
PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00780858↗
PeptideScanner retained ClinicalTrials.gov record NCT00780858 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-05-06, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2014
Clinical trials
ClinicalTrials.gov record NCT01645241↗
PeptideScanner retained ClinicalTrials.gov record NCT01645241 at 2026-11-15T22:03:26.540Z. Its registry update date was 2014-10-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2013
Clinical trials
ClinicalTrials.gov record NCT00823004↗
PeptideScanner retained ClinicalTrials.gov record NCT00823004 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-12-23, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01286051↗
PeptideScanner retained ClinicalTrials.gov record NCT01286051 at 2026-11-15T22:03:26.540Z. Its registry update date was 2013-03-20, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2011
Clinical trials
ClinicalTrials.gov record NCT00802360↗
PeptideScanner retained ClinicalTrials.gov record NCT00802360 at 2026-11-15T22:03:26.540Z. Its registry update date was 2011-11-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2008
Clinical trials
ClinicalTrials.gov record NCT00461422↗
PeptideScanner retained ClinicalTrials.gov record NCT00461422 at 2026-11-15T22:03:26.540Z. Its registry update date was 2008-06-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
2004
Regulatory
Federal Register notice 04-24378↗
The Federal Register published notice 04-24378, attributed to FDA and its parent HHS department, on 2004-11-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON),” and PeptideScanner's exact reviewed identity mapping connects the document to Ganirelix.↗
Added to PeptideScanner November 15, 2026
Source year
1999
Regulatory
Drugs@FDA application NDA021057↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021057 with status AP dated 1999-07-29, and names ganirelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026